Outlook Therapeutics Inc (OTLK) Stock Price, Quote & News

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company wa...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 619 3990

Website: www.outlooktherapeutics.com

Address:

111 S. Wood Avenue, Unit #100, Iselin, United States

Bennyman369 Dec. 5 at 4:16 PM

$OTLK $CAPR jump +7% on a $150 M public offering . 🤣🤣🤣 Who said dillution is bad. LOL

0 · Reply

AnalystLLM Dec. 5 at 4:14 PM

$OTLK easy to fake with slgo trade

0 · Reply

DAYMAN__ Dec. 5 at 4:13 PM

$OTLK pinning it

0 · Reply

AnalystLLM Dec. 5 at 4:08 PM

$OTLK all the drop is your great gift from warrants, breaking even + Eu & US not even started yet

0 · Reply

Mlewis0303 Dec. 5 at 4:00 PM

$OTLK I’d be happy if they just announced when earnings will be 🤣

1 · Reply

lucinith Dec. 5 at 3:55 PM

$OTLK go shorts go go !

0 · Reply

Consti22 Dec. 5 at 3:53 PM

$OTLK Hold on! 💪 It's almost here! 🎅

0 · Reply

Jojototo Dec. 5 at 3:43 PM

$OTLK im good I ain't selling any of my cheap shares when they were under 2$

0 · Reply

superOTLK Dec. 5 at 3:28 PM

$OTLK

0 · Reply

damn_the_torpedos Dec. 5 at 3:26 PM

$OTLK Yay more dilution

1 · Reply

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 22 days ago

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Nov 3, 2025, 8:35 AM EST - 4 weeks ago

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Sep 29, 2025, 8:45 AM EDT - 2 months ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 3, 2025, 8:35 AM EDT - 3 months ago

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Sep 2, 2025, 8:35 AM EDT - 3 months ago

Outlook Therapeutics Requests Type A Meeting with FDA

Aug 28, 2025, 11:51 AM EDT - 3 months ago

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

Aug 28, 2025, 11:15 AM EDT - 3 months ago

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Aug 28, 2025, 6:39 AM EDT - 3 months ago

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Aug 28, 2025, 6:30 AM EDT - 3 months ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Aug 24, 2025, 9:15 AM EDT - 3 months ago

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Aug 14, 2025, 8:05 AM EDT - 4 months ago

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Jul 24, 2025, 9:00 AM EDT - 4 months ago

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Jul 22, 2025, 8:45 AM EDT - 4 months ago

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 1, 2025, 8:05 AM EDT - 5 months ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jun 18, 2025, 9:05 AM EDT - 6 months ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 10, 2025, 8:05 AM EDT - 6 months ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 6 months ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

May 23, 2025, 6:30 AM EDT - 7 months ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 22, 2025, 4:01 PM EDT - 7 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 4:01 PM EDT - 7 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Apr 8, 2025, 8:45 AM EDT - 8 months ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Feb 28, 2025, 8:05 AM EST - 10 months ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 19, 2025, 9:00 AM EST - 10 months ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 14, 2025, 8:05 AM EST - 10 months ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 4, 2025, 9:05 AM EST - 10 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Jan 31, 2025, 8:05 AM EST - 11 months ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 23, 2025, 9:05 AM EST - 11 months ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 22, 2025, 9:05 AM EST - 11 months ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 16, 2025, 12:09 PM EST - 11 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS

Jan 16, 2025, 6:00 AM EST - 11 months ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Jan 6, 2025, 7:19 AM EST - 11 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO RCKT

Dec 27, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 13, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Streamlines Operations

Dec 4, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 3, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Announces Executive Leadership Transition

Nov 27, 2024, 9:27 AM EST - 1 year ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Nov 27, 2024, 6:50 AM EST - 1 year ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Nov 6, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Sep 16, 2024, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Sep 13, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Sep 4, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Sep 3, 2024, 8:45 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:11 AM EDT - 1 year ago

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

AMD

Aug 14, 2024, 12:02 PM EDT - 1 year ago

Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript

Aug 14, 2024, 7:05 AM EDT - 1 year ago

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Aug 12, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 7, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Bennyman369 Dec. 5 at 4:16 PM

$OTLK $CAPR jump +7% on a $150 M public offering . 🤣🤣🤣 Who said dillution is bad. LOL

0 · Reply

AnalystLLM Dec. 5 at 4:14 PM

$OTLK easy to fake with slgo trade

0 · Reply

DAYMAN__ Dec. 5 at 4:13 PM

$OTLK pinning it

0 · Reply

AnalystLLM Dec. 5 at 4:08 PM

$OTLK all the drop is your great gift from warrants, breaking even + Eu & US not even started yet

0 · Reply

Mlewis0303 Dec. 5 at 4:00 PM

$OTLK I’d be happy if they just announced when earnings will be 🤣

1 · Reply

lucinith Dec. 5 at 3:55 PM

$OTLK go shorts go go !

0 · Reply

Consti22 Dec. 5 at 3:53 PM

$OTLK Hold on! 💪 It's almost here! 🎅

0 · Reply

Jojototo Dec. 5 at 3:43 PM

$OTLK im good I ain't selling any of my cheap shares when they were under 2$

0 · Reply

superOTLK Dec. 5 at 3:28 PM

$OTLK

0 · Reply

damn_the_torpedos Dec. 5 at 3:26 PM

$OTLK Yay more dilution

1 · Reply

Bennyman369 Dec. 5 at 3:23 PM

$OTLK crazy!!! $CAPR is sit on $1.22B in MC with a positive phase 3 data. We are sit on $91M in MC with sales in UK/Germany started in June and a potential FDA apprabation in 3 weeks. 🤣🤣🤣🤣

2 · Reply

DAYMAN__ Dec. 5 at 3:20 PM

$OTLK looked amazing honestly

1 · Reply

Bennyman369 Dec. 5 at 3:20 PM

$OTLK 💎💎💎

0 · Reply

SilentJoker34 Dec. 5 at 3:15 PM

$OTLK 2 bux will seem real cheap when we're at $3.50-4.00 💎🇺🇲🧐

0 · Reply

lucinith Dec. 5 at 3:14 PM

$OTLK several hundred thousand shares shorted right now. Epic squeeze might be forming

0 · Reply

Knowledgeworthmore Dec. 5 at 3:06 PM

$OTLK the gang trying so hard to keep low, but we know what we have and they know how much drug worth so, they going to fight like hyenas.

0 · Reply

Lionzden90 Dec. 5 at 3:04 PM

$OTLK $SPY $BTC.X were the PCE Data numbers good?

0 · Reply

Act09pa Dec. 5 at 2:56 PM

$OTLK Just could not help myself…..no control Picked up some more cheap shares $2.05 gltal

0 · Reply

GenerallyGentle Dec. 5 at 2:55 PM

$OTLK my advice to day traders ... I would pause until after inflation data comes out in a few minutes. could be a huge liquidity grab in either direction.

0 · Reply

Lionzden90 Dec. 5 at 2:53 PM

$OTLK this is the cheapest you’ll get it. Eat up 🗣️🔥

0 · Reply

Bennyman369 Dec. 5 at 2:45 PM

$OTLK Look this beautiful lady!!!😍😍😍

2 · Reply

Bennyman369 Dec. 5 at 2:42 PM

$OTLK who want to eat that walls with me !!! 10h 😉 LfG!!!💪

2 · Reply

Market Cap	81.29M
Revenue (ttm)	0.00
Net Income (ttm)	-75.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.38

Volume	2,363,300
Avg Vol	3,346,004
Day's Range	N/A - N/A
Shares Out	44.42M
Stochastic %K	93%
Beta	0.17
Analysts	Sell
Price Target	$6.80